Conexeu Sciences Inc. began trading on Nasdaq on May 21, 2026, introducing a regenerative tissue platform called CXU™ that aims to address wound care, breast reconstruction, and aesthetic medicine. Their 3D-bioprinted B.R.E.A.S.T.™ matrix supports natural tissue regeneration, potentially transforming mastectomy reconstruction. The company holds patents across major regions and plans a 510(k) regulatory submission in early 2027. This public listing enables Conexeu to raise capital to advance its platform across multiple product lines in a growing regenerative medicine market.
Phemex has expanded its traditional finance (TradFi) offerings by introducing SPCXUSDT Pre-Market Perpetual Futures, allowing users to trade secondary-market prices linked to SpaceX in a 24/7 USDT-settled environment. This move aims to provide broade...
BizClik Media announced a Water Positivity Forum during Sustainability LIVE at London Climate Action Week on June 25, 2026. The invite-only event, sponsored by Philip Morris International, will gather over 250 senior sustainability executives to disc...
American Airlines shares edged up after initially falling in premarket trading, following the company's Q2 revenue forecast in line with estimates and an adjusted EPS outlook ranging from a small loss to a small profit. However, the airline lowered i...
Mexican courts ruled that Capstone Copper Corp. must pay over $50 million in unpaid royalties to Minera Portree de Zacatecas (MPZ) for its 2% Net Smelter Return royalty on five mining concessions at the Cozamin copper-silver mine, dating back to 2019...
At its 2026 Annual Shareholders Meeting, Michelin approved a €1.38 per share dividend payable on May 28, 2026. Philippe Jacquin was elected as the new General Manager, succeeding Yves Chapot. The meeting also re-elected several Supervisory Board memb...
